Inactive Instrument

Novartis AG Stock Xetra

Equities

NOT

CH0012005267

Pharmaceuticals

Sales 2024 * 48.16B 45.13B Sales 2025 * 49.98B 46.83B Capitalization 204B 191B
Net income 2024 * 10.65B 9.98B Net income 2025 * 11.58B 10.85B EV / Sales 2024 * 4.48 x
Net Debt 2024 * 12.16B 11.39B Net Debt 2025 * 10.8B 10.12B EV / Sales 2025 * 4.29 x
P/E ratio 2024 *
18.2 x
P/E ratio 2025 *
16.2 x
Employees 76,057
Yield 2024 *
3.93%
Yield 2025 *
4.06%
Free-Float 81.95%
More Fundamentals * Assessed data
Dynamic Chart
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years MT
Novartis: positive efficacy data in MS CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis DJ
Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB?s Bimzelx Poised to Further Disrupt the Market CI
Novartis reports positive interim results for Fabhalta CF
Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients MT
Novartis Gets Priority Review for Kidney Disease Treatment DJ
New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) DJ
Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta CI
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug MT
Health Care Slips on Risk Bias -- Health Care Roundup DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares DJ
Novartis: licensing agreement in prostate cancer CF
More news

Latest transcript on Novartis AG

Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company